Hanmi Pharm한미약품
128940 · KOSPI · ₩128940 · 한미약품
₩415,000▲ ₩26,500 (6.82%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 59.6% | 57.1% | 54.6% | 55.6% | 54.0% | 52.6% |
| Operating margin | 19.5% | 16.7% | 14.5% | 14.8% | 11.9% | 10.4% |
| Net margin | 13.1% | 11.0% | 8.1% | 9.8% | 6.2% | 5.6% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +7.0% | +3.5% | +0.3% | +12.0% | +10.7% | — |
| Operating income growth | +25.3% | +19.2% | −2.0% | +39.6% | +26.1% | — |
| Net income growth | +28.0% | +39.8% | −17.0% | +76.6% | +23.5% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 16.4% | 14.5% | 11.9% | 16.0% | 9.9% | 8.3% |
| Return on assets | 10.2% | 9.0% | 7.2% | 8.7% | 5.3% | 4.2% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 46.9% | 50.2% | 62.9% | 72.6% | 90.7% | 108.6% |
| Net debt to equity | −8.6% | 22.3% | 23.8% | 46.2% | 51.5% | 51.9% |
| Current ratio | 182.4% | 147.7% | 109.3% | 103.7% | 102.6% | 108.5% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Hanmi Pharm / 한미약품 / 128940 / KRX:128940
Source: KRX statistical information